Reference Message Network reported on May 9th according to a report on the website of the UK's Financial Times on May 7th, Novartis, one of the largest pharmaceutical companies in the world, said that China has shaped an image of stability and business friendliness by taking advantage of geopolitical turbulence. The pharmaceutical industry is currently striving to cope with the uncertainty of possible US tariffs and medical policies.
It was reported that Novartis CEO Vas Narasimhan recently attended the China Development Senior Forum, where dozens of business leaders from industries such as finance and energy were also present.
He told the Financial Times of the UK: "In the current global geopolitical environment, (China) sees an opportunity to be very business-friendly and stable." He added that China is "very open to multinational corporations."
Many enterprises are caught between two global powers, trying to enter the world's largest market without taking sides.
Foreign pharmaceutical companies have also been investing in China despite China's recent efforts to lower drug prices.
Pharmaceutical companies are eager to access China's vast market and cooperate with domestic enterprises with cutting-edge technology.
Vas Narasimhan hopes to collaborate with more Chinese biotechnology companies. He said that China's innovation level has sounded an "alarm" for Novartis and the pharmaceutical industry. They should seek new candidate drugs and technologies in China instead of viewing China as a place to obtain the results of "quick followers" research and development. (Translated by Hu Wei)
On November 8, 2024, at the 7th CIIE Medical Device and Health Care Exhibition, visitors learned about the treatment process of radioligand therapy through AR technology at the Novartis booth. (Xinhua News Agency)
Original article: https://www.toutiao.com/article/7502278134402990607/
Disclaimer: This article only represents the author's personal views. Please express your attitude by clicking the "Like/Dislike" button below.